title: Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy.
abstract: OBJECTIVE
  To assess the value of intensive intravenous (IV) fluid therapy and ascitic fluid aspiration in the management of severe ovarian hyperstimulation syndrome.
  
  
  METHODS
  Forty-two women with severe ovarian hyperstimulation syndrome were treated by ultrasonically guided transvaginal aspiration of ascitic fluid and IV fluid infusion. Ten women with the same condition treated conservatively constituted a comparison group. The main outcome measures included percentage change in hematocrit, creatinine clearance, and urine output before and after aspiration. The duration of hospital stay was compared between the groups.
  
  
  RESULTS
  Marked improvement of symptoms and general condition followed soon after aspiration. Hematocrit readings decreased by 22%, creatinine clearance increased by 79.3%, and urine output increased by 220.7%. The average volume of aspirated fluid was 3900 mL. The average duration of hospital stay was 3.8 days in the treated women. In the comparison group, severe symptoms and electrolyte imbalance continued for an average of 9 days, and the average hospital stay was 11 days.
  
  
  CONCLUSIONS
  Intensive IV fluid therapy and transvaginal aspiration of ascitic fluid are safe and effective in improving symptoms, preventing complications, and shortening the hospital stay in severe ovarian hyperstimulation syndrome.
authors.affiliation: Egyptian IVF-ET Center, Cairo University.
authors.forename: M A
authors.initials: MA
authors.lastname: Aboulghar
authors.forename: R T
authors.initials: RT
authors.lastname: Mansour
authors.forename: G I
authors.initials: GI
authors.lastname: Serour
authors.forename: M A
authors.initials: MA
authors.lastname: Sattar
authors.forename: Y M
authors.initials: YM
authors.lastname: Amin
authors.forename: I
authors.initials: I
authors.lastname: Elattar
mesh_terms: D001201:Ascites / Q000209:etiology / Q000628:therapy*; D005260:Female; D005440:Fluid Therapy; D006801:Humans; D007262:Infusions, Intravenous; D016471:Ovarian Hyperstimulation Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D010062:Ovulation Induction / Q000009:adverse effects; D013396:Suction / Q000379:methods